Best Oncology Companies in London, United Kingdom
The 79 best Oncology companies in London, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Achilles Therapeutics.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in London
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Achilles Therapeutics Developer of T-cell therapies for cancer | $242M | 47 mo ago | 118 | Charles Swanton Co-Founder | Public | 56 patents Neoantigen discovery and peptide synthesis for personalized cancer immunotherapy | — |
| 2 | Avacta Developer of drug delivery technology using tumor activated peptide linkers 24Funding top 21%News top 35%Moat top 38%Talent bottom 49% All 11 signals ▾Fundingtop 21% Newstop 35% Moattop 38% Talentbottom 49% Techbottom 47% Patentsbottom 42% Growthbottom 41% Globalbottom 41% Marketbottom 40% Innovationbottom 36% Fin. healthbottom 20% Funding: Raised $222M across 12 rounds · 12 rounds over 15 yrs (0.8/yr) News: 7 BI events in 12 mo (of 34 tracked, 8 types) · -46% YoY rank vs industry peers · Fliar Intelligence Index 24/100 | $222M | 8 mo ago | 90 90 → 47 (-48%) | Christina Coughlin CEO | Public | 17 patents Optical biosensor devices for nucleic acid analysis and reagent dispensing | — |
| 3 | Pheon Therapeutics Developer of antibody drug conjugates for treating solid tumor cancers | $188M | 25 mo ago | 8 | Bertrand Damour CEO | Series B | 37 patents Targeted antibody‑drug conjugates and novel cytotoxic small‑molecule therapeutics. | — |
| 4 | Autolus Clinical-stage biopharmaceutical provider developing CAR T therapies for cancer and autoimmune diseases | $181M | 28 mo ago | 51 | Martin Pule Founder | Public | 648 patents Patents concentrated in chemistry & materials | 1 award |
| 5 | Mereo BioPharma Developer of therapeutics for cancer and rare diseases | $141M | 72 mo ago | 56 56 → 45 (-20%) | Charles Sermon Co-Founder | Public | 273 patents Anti‑sclerostin antibodies for osteogenesis imperfecta and neutrophil elastase inhibitors for respiratory disease | — |
| 6 | Myricx Bio Developer of antibody drug conjugates for the treatment of cancer | $121M | 23 mo ago | 6 | Robin Carr CEO | Series A | — | — |
| 7 | Advanced Oncotherapy Provider of proton beam therapy system for the treatment of cancer | $84M | 39 mo ago | 157 | Nicolas Serandour CEO | Public | — | — |
| 8 | Cytospire Therapeutics Provider of immune cell engagers for treating cancer 53Funding top 24%Global top 45%Talent bottom 49% All 3 signals ▾Fundingtop 24% Globaltop 45% Talentbottom 49% Funding: Raised $83.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Global: Investors from 4 countries beyond United Kingdom rank vs industry peers · Fliar Intelligence Index 53/100 | $83M | 1 mo ago | — | Natalie Mount CEO | Series A | — | 1 award |
| 9 | Charm Therapeutics Developer of menin inhibitors designed for acute myeloid leukemia treatment 50Funding top 24%News top 29%Moat top 31%Growth top 32% All 8 signals ▾Fundingtop 24% Newstop 29% Moattop 31% Growthtop 32% Talenttop 33% Techbottom 49% Globalbottom 37% Marketbottom 29% Funding: Raised $70.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) News: 4 BI events in 12 mo (of 8 tracked, 3 types) · +300% YoY rank vs industry peers · Fliar Intelligence Index 50/100 | $70M | 10 mo ago | 16 16 → 32 (+100%) | Laksh Aithani Co-Founder & CEO | Series B | — | — |
| 10 | LabGenius Therapeutics Developer of an automated platform for therapeutic antibody discovery | $70M | 25 mo ago | — | James Field Founder & CEO | Series B | — | 1 job opening · 1 partnership |
| 11 | Prokarium Developer of bacterial immunotherapy treatments for various types of cancer | $62M | 41 mo ago | 20 20 → 17 (-15%) | Ibraheem Mahmood CEO | Series C | 77 patents Patents concentrated in health & consumer products | — |
| 12 | Ixaka Developer of cell-based therapeutic solutions for the treatment of multiple therapeutic conditions | $54M | 65 mo ago | 9 | Vicente Gonzalez Co-Founder | Deadpooled | — | — |
| 13 | Epsilogen Developer of immunoglobulinE antibodies for the treatment of cancer | $54M | 21 mo ago | 4 | Tim Wilson CEO at Epsilogen Ltd | Series B | 19 patents Engineered therapeutic antibodies, especially IgE and hybrid formats targeting HER2 low-expression cancers | — |
| 14 | Adaptate Biotherapeutics Developer of T-cell based immunotherapy for treating cancer | $34M | 62 mo ago | 21 | — | Acquired | 4 patents Engineered antibodies targeting TCR delta variable 1 for immunotherapy | — |
| 15 | Kesios Therapeutics Small molecule drugs for haematological malignancies, such as multiple myeloma | $32M | 126 mo ago | 1 | — | Deadpooled | — | — |
| 16 | Actimed Therapeutics Develoeper of therapies for treating cancer and other chronic diseases | $25M | 30 mo ago | 4 | Andrew Stewart Coats Founder and Director | Series A | 93 patents Patents concentrated in health & consumer products | — |
| 17 | Tiziana Life Sciences Developer of small-molecule drugs for cancer and autoimmune diseases | $22M | 79 mo ago | 11 | — | Public | 79 patents Patents concentrated in chemistry & materials | — |
| 18 | Treos Bio Developer of cancer vaccines and companion diagnostics | $22M | 62 mo ago | 12 12 → 16 (+33%) | — | Series B | 65 patents Personalized peptide-based cancer vaccines and immunogenic peptide discovery platforms | — |
| 19 | Leucid Bio Developer of therapeutics for the treatment of cancers | $22M | 60 mo ago | 10 10 → 23 (+130%) | John Maher Co-Founder | Series A | — | — |
| 20 | LIfT Biosciences Developer of neutrophil-based cell therapies for solid tumors | $20M | 10 mo ago | 8 | — | Series A | 69 patents Manufacturing and therapeutic use of engineered immune cells for cancer treatment | — |
| 21 | Valink Therapeutics Developer of bispecific antibody-drug conjugate therapeutics for oncology and other diseases | $20M | 8 mo ago | — | Irsyad Khairil Co-Founder & CTO | Seed | — | — |
| 22 | Capella Bioscience Monoclonal antibodies (mAbs) in oncology and autoimmune disease. | $18M | 101 mo ago | 3 | — | Series A | 24 patents Therapeutic antibodies targeting LIGHT, BDCA‑2, and PD‑L1 for immune modulation | — |
| 23 | Valirx Developer of novel technologies and products in oncology therapeutics and diagnostics | $14M | 84 mo ago | 7 | — | Public | 16 patents Patents concentrated in chemistry & materials | 2 partnerships |
| 24 | Macrophage Pharma Developer of small molecule drugs targeting tumor-associated macrophages | $11M | 106 mo ago | 7 | — | Series A | 54 patents Immuno‑oncology cytokine therapies (IL‑12/IFN‑γ) and p38 MAPK inhibitor drug development. | — |
| 25 | 4C Biomed Developer of immuno-therapeutics for the treatment of cancer and autoimmune diseases | $10M | 35 mo ago | 1 | Eyal Greenberg Chief Executive Officer | Seed | 43 patents Immuno‑oncology: HVEM‑targeted therapeutic antibodies and PD‑1/PD‑L1 response biomarkers. | — |
| 26 | Ignota Labs AI-driven toxicity prediction tools for early-stage drug discovery scientists | $7M | 15 mo ago | 9 | Layla Hosseini-Gerami Co-Founder | Seed | — | 2 partnerships · 1 award |
| 27 | NK:IO Developer of small molecule therapies for hematological and solid tumors | $7M | 18 mo ago | 1 | Matthew Fuchter Co-Founder | Seed | — | — |
| 28 | Plasticell Developer of stem cell technologies to discover drugs that regenerate tissues of the human body | $6M | 92 mo ago | 8 | Yen Choo Founder & Chairman | Series A | 75 patents Cell reprogramming, differentiation, and stem‑cell manufacturing for regenerative therapies | — |
| 29 | Evariste AI-based drug discovery platform to target synthetic lethal pathways in oncology | $4M | 33 mo ago | 9 | Anna Hercot CEO | Seed | — | — |
| 30 | Aptorum Group Developer of small molecular therapeutics for multiple disorders | $3M | 42 mo ago | 26 | Ian Huen Founder & CEO | Public | — | — |
| 31 | VacV Developer of immuno-therapeutics for cancer treatment | $3M | 43 mo ago | 6 | Peng Liu Co-Founder | Seed | — | — |
| 32 | Siftr Bio Developer of antibofy drug conjugates for cancer treatment | $1M | 18 mo ago | — | Ed Tate Co-Founder | Seed | — | — |
| 33 | Ellipses Pharma Developer of therapies for treating cancer | $1M | 23 mo ago | 27 | Christopher Evans Founder & Chairman | Seed | 67 patents Targeted combination therapies for AR‑positive breast cancer using BCL‑2 and epigenetic inhibitors | — |
| 34 | BeamLine Diagnostics Provider of bedside pre-screening technology for cancer | $1M | 108 mo ago | 7 | — | Deadpooled | 10 patents Single-cell FTIR spectroscopy for cellular identification and disease diagnostics | — |
| 35 | Nanovery Developer of nanobots for diagnosing cancer | $655K | 14 mo ago | 1 | Roma Galloway Co-Founder & COO | Seed | 9 patents Catalytic nucleic‑acid nanostructures for programmable molecular sensing and diagnostics | — |
| 36 | Mursla Provider of diagnostic device for cancer detection | $547K | 69 mo ago | 9 | Victor Serdio Co-Founder | Seed | 32 patents Isolation, characterization, and biosensor conditioning of tissue-specific extracellular vesicles. | 1 award |
| 37 | Oppilotech Provider of computational modelling platform to simulate biological processes | $483K | 97 mo ago | 3 | Ajay Mistry Co-Founder & CEO | Seed | — | — |
| 38 | BioMoti Developer of therapeutics for cancer-based on targeted delivery of drugs to tumor cells | $439K | 62 mo ago | 1 | Joanne Martin Co-Founder | Seed | — | — |
| 39 | Odin Vision Provider of AI-based colon cancer detection platform | $368K | 85 mo ago | 12 | — | Acquired | — | — |
| 40 | CELEX Oncology Provides technology for stopping benign tumors transform | $326K | 109 mo ago | 3 | — | Seed | 37 patents Targeting Nav1.5 sodium channel to inhibit cancer metastasis and invasion. | — |
| 41 | Anastasis Biotec Developer of cancer therapeutics | $310K | 70 mo ago | 3 | Agamemnon Epenetos CEO | Seed | 8 patents Cell-penetrating peptide conjugates for intracellular delivery of therapeutic proteins/peptides. | — |
| 42 | Feedback Medical Provider of medical imaging analysis platform | — | 54 mo ago | 18 18 → 29 (+61%) | Tom Oakley CEO | Public | — | 1 launch |
Top 12 Oncology companies in London
#1
Series A · London, England · founded 2023$83Mraised▾
Provider of immune cell engagers for treating cancer. It offers a portfolio of differentiated multispecific engager antibodies to enhance and direct the activity of innate and adaptive effector immune cells to discriminate between target diseased vs healthy cell for the treatment of solid tumors and other cancer.
- May 2026Series A$83M
- Seed—
#2
Public · London, England · founded 2006 · 90 employees$222.2Mraised▾
Developer of drug delivery technology using tumor activated peptide linkers. This technology attaches peptides to existing therapeutic agents to maintain them in an inactive state while circulating in the bloodstream. The drug remains inactive until it reaches the tumor site, where specific enzymes remove the peptide to release the active medication. This mechanism concentrates the therapeutic effect within the tumor environment.
- Oct 2025Post IPO$21.5M
- Aug 2025Post IPO$4.4M
- Feb 2024Post IPO$32.5M
- Nov 2022Post IPO$73.1M
#3
Series B · London, England · founded 2021 · 16 employees$70Mraised▾
Developer of menin inhibitors designed for acute myeloid leukemia treatment. The focus is on designing structurally optimised inhibitors that bind within the KMT2A interface. The aim is to overcome treatment resistance in acute myeloid leukemia.
- Aug 2025Series B$80M
- Apr 2023Series A$20M
- Jun 2022Series A$50M
#4
Seed · London, England · founded 2020$19.6Mraised▾
Developer of bispecific antibody-drug conjugate therapeutics for oncology and other diseases. The company focuses on creating more effective drugs that differentiate between diseased and healthy cells. It utilizes a discovery engine built on synthetic protein biology, high-throughput functional screening, and artificial intelligence. The company is advancing oncology-focused programs.
- Oct 2025Seed$11.8M
- Nov 2023Seed$7.8M
#5
Series A · London, England · founded 2016 · 8 employees$20.1Mraised▾
Developer of neutrophil-based cell therapies for solid tumors. The company has allogeneic innate immune-cell therapy platform called Neutrophil only leukocyte infusion therapy (N-LIfT) that allows to produce different types of Immunomodulatory alpha neutrophils (IMANs) at scale from iPSCs for a wide range of different purposes to treat cancers, autoimmune diseases, neurological conditions and antimicrobial resistance.
- Jul 2025Grant (prize money)$14M
- Sep 2024Series A$13.3M
- May 2024Grant (prize money)$1M
- Oct 2023Series A—
#6
Series A · London, England · founded 2019 · 6 employees$120.6Mraised▾
Developer of antibody drug conjugates for the treatment of cancer. The company focuses on the development of a pipeline of proprietary differentiated antibody drug conjugates based on novel N-myristoyltransferase inhibitor (NMTi) payload chemistry platform to address serious unmet needs in oncology.
- Jul 2024Series A$114M
- Oct 2019Seed$6.6M
#7
Series B · London, England · founded 2016 · 4 employees$53.8Mraised▾
Developer of immunoglobulin antibodies for the treatment of cancer. It offers antibodies that help in the treatment of solid tumors. The lead product candidate, MOv18 IgE is for folate receptor alpha positive cancer patients. Other products include EPS 201 for breast cancer and gastric problems.
- Sep 2024Series B$16.4M
- Mar 2022Series B$41.1M
- Oct 2020Grant (prize money)—
- Jul 2020Grant (prize money)$627.7K
#8
Series B · London, England · founded 2022 · 8 employees$188Mraised▾
Developer of antibody drug conjugates for treating solid tumor cancers. These therapeutic agents utilize monoclonal antibodies to target specific proteins on cancer cells. The technology employs proprietary payloads and linker combinations to deliver cytotoxic agents directly to tumor sites. This approach aims to balance safety and efficacy by minimizing exposure to healthy tissue while addressing unmet medical needs in oncology.
- May 2024Series B$120M
- Sep 2022Series A$68M
#9
Public · London, England · founded 2015 · 51 employees$181.4Mraised▾
Clinical-stage biopharmaceutical provider developing CAR T therapies for cancer and autoimmune diseases. It leverages advanced immune cell engineering, chimeric antigen receptor (CAR) technology, and proprietary T cell programming platforms to create precise, controlled, and highly active therapeutic products designed to improve patient outcomes. Its technology platform combines innovative cell programming capabilities with proprietary viral vector systems and semi-automated manufacturing processes to engineer patient-derived T cells capable of recognizing and eliminating disease-causing cells.
- Feb 2024Post IPO$200M
- Nov 2021Post IPO—
- Sep 2017Series C$80M
- Mar 2016Series B$56M
#10
Seed · London, England · founded 2021 · 9 employees$6.9Mraised▾
Ignota Labs is a technology startup in the pharmaceutical sector that provides AI-driven toxicity prediction tools for early-stage drug discovery scientists. Their suite of tools, TOXSCAPE, helps scientists identify and understand safety issues during the drug discovery process, reducing expensive setbacks and delays.
- Feb 2025Seed$6.9M
#11
Series B · London, England · founded 2012$69.5Mraised▾
Developer of an automated platform for therapeutic antibody discovery. This platform rapidly identifies and co-optimizes complex therapeutic antibodies across multiple key properties. The technology focuses on developing selectivity-enhanced antibodies for solid tumor treatment, aiming to deliver antibodies with superior killing profiles. The platform is modality and format-agnostic, offering a solution to the challenges of engineering complex antibodies where the relationship between design and function is often non-intuitive. This approach addresses the limitations of conventional methods that may yield sub-optimal molecules.
- May 2024Series B$44.5M
- Oct 2022Grant (prize money)—
- Oct 2020Series A$15M
- Oct 2019Series A$10M
#12
Seed · London, England · founded 2020 · 1 employees$6.5Mraised▾
Developer of small molecule therapies for hematological and solid tumors. The company is pioneering discoveries in small molecule and peptide ligand activation of blood stem cell progenitors and NK cells for the treatment of cancer.
- Dec 2024Seed$127.3K
- May 2024Seed$973.3K
- Jul 2023Seed$1.5M
- Jul 2023Grant (prize money)$2.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology in London is moving
A read on the academic research around Oncology in London — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 418 papers.
- University College London121
- Imperial College London99
- King\'s College London96
- Queen Mary University of London84
- London Cancer26
- Tumor microenvironment6→46
- Immunotherapy2→35
- Cancer research11→42
- Immune system4→28
- Cancer immunotherapy2→20
- Tumor microenvironment7→72
- Immune system1→65
- Immunotherapy3→62
- Cancer research8→48
- Stromal cell1→11
- Immunotherapy2→25
- Immune system1→17
- Cancer2→17
- Cancer immunotherapy1→10
- Cancer research1→9
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.